Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263).
作者： Jianlin Qiao , Simone M. Schoenwaelder , Kylie D. Mason , Huy Tran , Amanda K. Davis
DOI: 10.1182/BLOOD-2012-12-467415
关键词:
摘要: To the editor: Leukemia cells express high levels of Bcl-2[1][1] and BH3 mimetics that antagonize prosurvival function Bcl-2 related proteins, thereby inducing apoptosis, are useful treatments for patients with chemotherapy-refractory leukemia.[2][2] such as ABT-737 ABT-
ashpublications.org
bloodjournal.org参考文章(10)
Susan M. O'Brien, David F. Claxton, Michael Crump, Stefan Faderl, Thomas Kipps, Michael J. Keating, Jean Viallet, Bruce D. Cheson, Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia Blood. ,vol. 113, pp. 299- 305 ,(2009) , 10.1182/BLOOD-2008-02-137943
Simone M. Schoenwaelder, Kate E. Jarman, Elizabeth E. Gardiner, My Hua, Jianlin Qiao, Michael J. White, Emma C. Josefsson, Imala Alwis, Akiko Ono, Abbey Willcox, Robert K. Andrews, Kylie D. Mason, Hatem H. Salem, David C. S. Huang, Benjamin T. Kile, Andrew W. Roberts, Shaun P. Jackson, Bcl-xL inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets Blood. ,vol. 118, pp. 1663- 1674 ,(2011) , 10.1182/BLOOD-2011-04-347849
Kylie D Mason, Marina R Carpinelli, Jamie I Fletcher, Janelle E Collinge, Adrienne A Hilton, Sarah Ellis, Priscilla N Kelly, Paul G Ekert, Donald Metcalf, Andrew W Roberts, David CS Huang, Benjamin T Kile, None, Programmed Anuclear Cell Death Delimits Platelet Life Span Cell. ,vol. 128, pp. 1173- 1186 ,(2007) , 10.1016/J.CELL.2007.01.037
Jane F. Arthur, Elizabeth E. Gardiner, Robert K. Andrews, Mohammad Al-Tamimi, Focusing on plasma glycoprotein VI. Thrombosis and Haemostasis. ,vol. 107, pp. 648- 655 ,(2012) , 10.1160/TH11-10-0745
Carlo Visco, Marco Ruggeri, Maria Laura Evangelista, Roberto Stasi, Roberta Zanotti, Ilaria Giaretta, Achille Ambrosetti, Domenico Madeo, Giovanni Pizzolo, Francesco Rodeghiero, Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia Blood. ,vol. 111, pp. 1110- 1116 ,(2008) , 10.1182/BLOOD-2007-09-111492
Mohammad Al-Tamimi, Fi-Tjen Mu, Masaaki Moroi, Elizabeth E. Gardiner, Michael C. Berndt, Robert K. Andrews, Measuring soluble platelet glycoprotein VI in human plasma by ELISA Platelets. ,vol. 20, pp. 143- 149 ,(2009) , 10.1080/09537100802710286
Andrew W. Roberts, John F. Seymour, Jennifer R. Brown, William G. Wierda, Thomas J. Kipps, Seong Lin Khaw, Dennis A. Carney, Simon Z. He, David C.S. Huang, Hao Xiong, Yue Cui, Todd A. Busman, Evelyn M. McKeegan, Andrew P. Krivoshik, Sari H. Enschede, Rod Humerickhouse, Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease Journal of Clinical Oncology. ,vol. 30, pp. 488- 496 ,(2012) , 10.1200/JCO.2011.34.7898
Elizabeth E. Gardiner, Jane F. Arthur, Mark L. Kahn, Michael C. Berndt, Robert K. Andrews, Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase Blood. ,vol. 104, pp. 3611- 3617 ,(2004) , 10.1182/BLOOD-2004-04-1549
Peter Hillmen, Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future. Journal of Clinical Oncology. ,vol. 30, pp. 469- 470 ,(2012) , 10.1200/JCO.2011.37.8612
Christin Tse, Alexander R. Shoemaker, Jessica Adickes, Mark G. Anderson, Jun Chen, Sha Jin, Eric F. Johnson, Kennan C. Marsh, Michael J. Mitten, Paul Nimmer, Lisa Roberts, Stephen K. Tahir, Yu Xiao, Xiufen Yang, Haichao Zhang, Stephen Fesik, Saul H. Rosenberg, Steven W. Elmore, ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor Cancer Research. ,vol. 68, pp. 3421- 3428 ,(2008) , 10.1158/0008-5472.CAN-07-5836